BRCA 2023: Moving Into the Mainstream represents a unique opportunity to look at all aspects of breast and ovarian cancer, and in particular the susceptibility genes, BRCA1 and BRCA2, which are responsible for a considerable fraction of early-onset breast cancer.
Clinicians and researchers from over 30 countries will gather virtually for the ninth edition of this event which has come to be recognized as THE major international conference in the world that covers specific targeted therapies for hereditary cancer.
Topics covered will include population-based testing for HBOC-related genes, new approaches to the early diagnosis of hereditary cancers, new developments in HBOC management, polygenic risk scores, and special round tables on disparities in hereditary cancer genetics and mainstreaming genetic testing for HBOC, to name just a few.
Interested participants are invited to submit abstracts on topics related to hereditary breast, ovarian, prostate and pancreatic cancer. Submissions are welcome from all disciplines. Click here to go to the Call for Abstracts page.
Deadline for Oral Abstract Submissions: December 2, 2022
Deadline for Poster Abstract Submissions: January 13, 2023
The tradition of a one day public conference for those Living with BRCA, their families and friends, will continue as part of our commitment to educate and inform the wider population about BRCA 1/2. Click here.